{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:14:27Z","timestamp":1781648067411,"version":"3.54.5"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82074427"],"award-info":[{"award-number":["82074427"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017950","name":"Shanghai Municipal Health Commission","doi-asserted-by":"publisher","award":["20224Z0019"],"award-info":[{"award-number":["20224Z0019"]}],"id":[{"id":"10.13039\/100017950","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.intimp.2023.110553","type":"journal-article","created":{"date-parts":[[2023,7,20]],"date-time":"2023-07-20T14:27:15Z","timestamp":1689863235000},"page":"110553","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Efficacy and safety of biological agents to treat patients with palmoplantar pustulosis: A systematic scoping review"],"prefix":"10.1016","volume":"122","author":[{"given":"Miao","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Hua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seokgyeong","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoying","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaqiong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunxiao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naixuan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2525-9679","authenticated-orcid":false,"given":"Xin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 5","key":"10.1016\/j.intimp.2023.110553_b0005","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/jdv.12561","article-title":"Treatment for palmoplantar pustular psoriasis: systematic literature review, evidence-based recommendations and expert opinion","volume":"28","author":"Sevrain","year":"2014","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"issue":"3","key":"10.1016\/j.intimp.2023.110553_b0010","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1080\/1744666X.2019.1708194","article-title":"The clinical, humanistic, and economic burden of palmoplantar pustulosis: a structured review","volume":"16","author":"Kharawala","year":"2020","journal-title":"Expert Rev. Clin. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2023.110553_b0015","doi-asserted-by":"crossref","first-page":"e006450","DOI":"10.1136\/bmjopen-2014-006450","article-title":"Epidemiology of psoriasis and palmoplantar pustulosis: a nationwide study using the Japanese national claims database","volume":"5","author":"Kubota","year":"2015","journal-title":"BMJ Open"},{"issue":"9","key":"10.1016\/j.intimp.2023.110553_b0020","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1016\/j.jid.2016.04.038","article-title":"IL36RN Mutations Affect Protein Expression and Function: A Basis for Genotype-Phenotype Correlation in Pustular Diseases","volume":"136","author":"Tauber","year":"2016","journal-title":"J, Invest. Dermatol."},{"issue":"3","key":"10.1016\/j.intimp.2023.110553_b0025","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.ajhg.2011.07.022","article-title":"Mutations in IL36RN\/IL1F5 are associated with the severe episodic inflammatory skin disease known as generalized pustular psoriasis","volume":"89","author":"Onoufriadis","year":"2011","journal-title":"Am. J. Hum. Genet."},{"issue":"11","key":"10.1016\/j.intimp.2023.110553_b0030","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1016\/j.jid.2016.06.618","article-title":"AP1S3 Mutations Cause Skin Autoinflammation by Disrupting Keratinocyte Autophagy and Up-Regulating IL-36 Production","volume":"136","author":"Mahil","year":"2016","journal-title":"J, Invest. Dermatol."},{"issue":"3","key":"10.1016\/j.intimp.2023.110553_b0035","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1111\/bjd.15867","article-title":"The genetic basis for most patients with pustular skin disease remains elusive","volume":"178","author":"M\u00f6ssner","year":"2018","journal-title":"Br. J. Dermatol."},{"issue":"1","key":"10.1016\/j.intimp.2023.110553_b0040","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jdermsci.2020.03.003","article-title":"Palmoplantar pustulosis: Current understanding of disease definition and pathomechanism","volume":"98","author":"Murakami","year":"2020","journal-title":"J. Dermatol. Sci."},{"issue":"2","key":"10.1016\/j.intimp.2023.110553_b0045","first-page":"109","article-title":"General Characteristics and Comorbidities in Patients with Palmoplantar Pustulosis","volume":"26","author":"Misiak-Galazka","year":"2018","journal-title":"Acta Dermatovenerol. Croat."},{"issue":"411","key":"10.1016\/j.intimp.2023.110553_b0050","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aan2514","article-title":"An analysis of IL-36 signature genes and individuals with IL1RL2 knockout mutations validates IL-36 as a psoriasis therapeutic target","volume":"9","author":"Mahil","year":"2017","journal-title":"Sci. Transl. Med."},{"issue":"1","key":"10.1016\/j.intimp.2023.110553_b0055","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jdermsci.2016.09.019","article-title":"Palmoplantar pustular psoriasis (PPPP) is characterized by activation of the IL-17A pathway","volume":"85","author":"Bissonnette","year":"2017","journal-title":"J. Dermatol. Sci."},{"key":"10.1016\/j.intimp.2023.110553_b0060","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration","volume":"339","author":"Liberati","year":"2009","journal-title":"BMJ"},{"issue":"5","key":"10.1016\/j.intimp.2023.110553_b0065","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.jaad.2019.01.066","article-title":"Secukinumab for moderate-to-severe palmoplantar pustular psoriasis: Results of the 2PRECISE study","volume":"80","author":"Mrowietz","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"issue":"10","key":"10.1016\/j.intimp.2023.110553_b0070","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1001\/jamadermatol.2019.1394","article-title":"Efficacy and Safety of Guselkumab in Japanese Patients With Palmoplantar Pustulosis: A Phase 3 Randomized Clinical Trial","volume":"155","author":"Terui","year":"2019","journal-title":"JAMA Dermatol."},{"issue":"2","key":"10.1016\/j.intimp.2023.110553_b0075","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s13555-021-00504-0","article-title":"Spesolimab, an Anti-Interleukin-36 Receptor Antibody, in Patients with Palmoplantar Pustulosis: Results of a Phase IIa, Multicenter, Double-Blind, Randomized, Placebo-Controlled Pilot Study","volume":"11","author":"Mrowietz","year":"2021","journal-title":"Dermatol. Ther. (Heidelb)"},{"issue":"2","key":"10.1016\/j.intimp.2023.110553_b0080","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/bjd.20653","article-title":"Anakinra for palmoplantar pustulosis: results from a randomized, double-blind, multicentre, two-staged, adaptive placebo-controlled trial (APRICOT)*","volume":"186","author":"Cro","year":"2022","journal-title":"Br. J. Dermatol."},{"issue":"3","key":"10.1016\/j.intimp.2023.110553_b0085","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1001\/jamadermatol.2017.5937","article-title":"Efficacy and Safety of Guselkumab, an Anti-interleukin 23 Monoclonal Antibody, for Palmoplantar Pustulosis: A Randomized Clinical Trial","volume":"154","author":"Terui","year":"2018","journal-title":"JAMA Dermatol."},{"issue":"10","key":"10.1016\/j.intimp.2023.110553_b0090","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1111\/jdv.12272","article-title":"Increased expression of IL-17A and limited involvement of IL-23 in patients with palmo-plantar (PP) pustular psoriasis or PP pustulosis; results from a randomised controlled trial","volume":"28","author":"Bissonnette","year":"2014","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"issue":"12","key":"10.1016\/j.intimp.2023.110553_b0095","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1111\/j.1468-3083.2011.03984.x","article-title":"Treatment of palmoplantar psoriasis with infliximab: a randomized, double-blind placebo-controlled study","volume":"25","author":"Bissonnette","year":"2011","journal-title":"J. Eur. Acad. Dermatol. Venereol.: JEADV"},{"key":"10.1016\/j.intimp.2023.110553_b0100","doi-asserted-by":"crossref","unstructured":"Index, in Cochrane Handbook for Systematic Reviews of Interventions. 2019. pp. 659\u2013694.","DOI":"10.1002\/9781119536604.index"},{"issue":"12","key":"10.1016\/j.intimp.2023.110553_b0105","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1111\/1346-8138.16132","article-title":"Sustained efficacy and safety of guselkumab in patients with palmoplantar pustulosis through 1.5 years in a randomized phase 3 study","volume":"48","author":"Okubo","year":"2021","journal-title":"J. Dermatol."},{"issue":"2","key":"10.1016\/j.intimp.2023.110553_b0110","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/bjd.20653","article-title":"Anakinra for palmoplantar pustulosis: results from a randomized, double-blind, multicentre, two-staged, adaptive placebo-controlled trial (APRICOT)","volume":"186","author":"Cro","year":"2021","journal-title":"Br. J. Dermatol."},{"issue":"10","key":"10.1016\/j.intimp.2023.110553_b0115","first-page":"940","article-title":"Etanercept in the treatment of palmoplantar pustulosis","volume":"7","author":"Bissonnette","year":"2008","journal-title":"J. Drugs Dermatol."},{"issue":"6","key":"10.1016\/j.intimp.2023.110553_b0120","doi-asserted-by":"crossref","DOI":"10.3390\/nu13062010","article-title":"Potential Role of Probiotics in Ameliorating Psoriasis by Modulating Gut Microbiota in Imiquimod-Induced Psoriasis-Like Mice","volume":"13","author":"Lu","year":"2021","journal-title":"Nutrients"},{"issue":"3","key":"10.1016\/j.intimp.2023.110553_b0125","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/1346-8138.15196","article-title":"Japanese guidance for use of biologics for psoriasis (the 2019 version)","volume":"47","author":"Saeki","year":"2020","journal-title":"J. Dermatol."},{"issue":"4","key":"10.1016\/j.intimp.2023.110553_b0130","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s40257-016-0191-7","article-title":"Palmoplantar Psoriasis and Palmoplantar Pustulosis: Current Treatment and Future Prospects","volume":"17","author":"Raposo","year":"2016","journal-title":"Am. J. Clin. Dermatol."},{"issue":"4","key":"10.1016\/j.intimp.2023.110553_b0135","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s13555-017-0207-0","article-title":"The Efficacy of Biologic Therapy for the Management of Palmoplantar Psoriasis and Palmoplantar Pustulosis: A Systematic Review","volume":"7","author":"Sanchez","year":"2017","journal-title":"Dermatol. Ther. (Heidelb)"},{"issue":"1","key":"10.1016\/j.intimp.2023.110553_b0140","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.clindermatol.2016.09.004","article-title":"Palmoplantar psoriasis","volume":"35","author":"Engin","year":"2017","journal-title":"Clin. Dermatol."},{"issue":"4","key":"10.1016\/j.intimp.2023.110553_b0145","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1111\/bjd.12150","article-title":"Efficacy of ustekinumab in refractory palmoplantar pustular psoriasis","volume":"168","author":"Morales-M\u00fanera","year":"2013","journal-title":"Br. J. Dermatol."},{"issue":"10","key":"10.1016\/j.intimp.2023.110553_b0150","doi-asserted-by":"crossref","DOI":"10.1111\/ijd.12511","article-title":"Efficacy of ustekinumab in palmoplantar pustulosis and palmoplantar pustular psoriasis","volume":"53","author":"Bertelsen","year":"2014","journal-title":"Int. J. Dermatol."},{"issue":"8","key":"10.1016\/j.intimp.2023.110553_b0155","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1080\/14740338.2020.1785427","article-title":"Biologics in the treatment of pustular psoriasis","volume":"19","author":"Wang","year":"2020","journal-title":"Expert Opin. Drug Saf."},{"issue":"6","key":"10.1016\/j.intimp.2023.110553_b0160","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1111\/bjd.19560","article-title":"Interventions for chronic palmoplantar pustulosis: abridged Cochrane systematic review and GRADE assessments","volume":"184","author":"Obeid","year":"2021","journal-title":"Br. J. Dermatol."},{"issue":"2","key":"10.1016\/j.intimp.2023.110553_b0165","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1046\/j.1365-2133.1999.02963.x","article-title":"Clinical measures of disease severity and outcome in psoriasis: a critical appraisal of their quality","volume":"141","author":"Ashcroft","year":"1999","journal-title":"Br. J. Dermatol."},{"issue":"6","key":"10.1016\/j.intimp.2023.110553_b0170","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1037\/0278-6133.17.6.530","article-title":"Interpersonal concerns and psychological difficulties of psoriasis patients: effects of disease severity and fear of negative evaluation","volume":"17","author":"Leary","year":"1998","journal-title":"Health Psychol."},{"issue":"6","key":"10.1016\/j.intimp.2023.110553_b0175","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.jaad.2008.11.910","article-title":"Palmoplantar psoriasis: a phenotypical and clinical review with introduction of a new quality-of-life assessment tool","volume":"60","author":"Farley","year":"2009","journal-title":"J. Am. Acad. Dermatol."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576923008767?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576923008767?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T04:53:04Z","timestamp":1778820784000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576923008767"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":35,"alternative-id":["S1567576923008767"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2023.110553","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of biological agents to treat patients with palmoplantar pustulosis: A systematic scoping review","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2023.110553","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"110553"}}